Citadel Advisors
AURA icon

Citadel Advisors’s Aura Biosciences AURA Stock Holding History

Citadel Advisors’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,000
Closed -$35.2K – 12482
2025
Q1 		$35.2K Buy
6,000
+4,100
+216% +$31K ﹤0.01% 12657
2024
Q4 		$15.6K Sell
1,900
-29,700
-94% -$280K ﹤0.01% 13340
2024
Q3 		$282K Buy
31,600
+30,800
+3,850% +$264K ﹤0.01% 9466
2024
Q2 		$6.05K Buy
800
+400
+100% +$2.93K ﹤0.01% 13363
2024
Q1 		$3.14K Buy
400
+200
+100% +$1.66K ﹤0.01% 13942
2023
Q4 		$1.77K Buy
+200
New +$1.69K ﹤0.01% 13778
2023
Q3 		– Sell
-1,000
Closed -$12.3K – 14257
2023
Q2 		$12.3K Buy
+1,000
New +$10.7K ﹤0.01% 13083

Other funds holding AURA

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Citadel Advisors's AURA Position: Q1 2026 in Review

Citadel Advisors reduced its Aura Biosciences (AURA) stake by 82% in Q1 2026, selling an estimated $322K and leaving 12,503 shares worth $83.6K. The position accounts for ﹤0.01% of the portfolio, ranked #12148.

Citadel Advisors first reported a position in AURA in Q4 2021 and has held it in 17 quarters since. The position peaked at $48.3M in Q1 2022. 126 funds tracked by Wall St. Rank hold AURA as of Q1 2026.

  • Citadel Advisors held 12,503 shares of Aura Biosciences worth $83.6K as of Q1 2026.
  • Citadel Advisors sold 56,046 Aura Biosciences shares in Q1 2026, an estimated $322K.
  • Aura Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12148 holding.
  • Citadel Advisors first reported a position in Aura Biosciences in Q4 2021 and has held it in 17 quarters since.
  • Citadel Advisors's Aura Biosciences position peaked at $48.3M in Q1 2022.
  • 126 funds tracked by Wall St. Rank held Aura Biosciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.